Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Bladder Cancer, May 2024

Free Subscription


Abstracts

Retrieve all available abstracts of the following 185 articles:
HTML format


 

Single Articles

  1. PRAHARAJ M, Shen F, Lee AJ, Zhao L, et al
    Metabolic reprogramming of tumor-associated macrophages using glutamine antagonist JHU083 drives tumor immunity in myeloid-rich prostate and bladder cancer tumors.
    Cancer Immunol Res. 2024 May 3. doi: 10.1158/2326-6066.CIR-23-1105.
    PubMed    
    Abstract available

  2. YE Z, Liu C, Wu S, Jin X, et al
    Identification of cuproptosis-related long non-coding RNA and construction of a novel prognostic signature for bladder cancer: An observational study.
    Medicine (Baltimore). 2024;103:e38005.
    PubMed    
    Abstract available

  3. LIN FX, Wang L, Xu ZP
    A balanced perspective on bladder preservation and systemic treatment in muscle-invasive bladder cancer.
    World J Urol. 2024;42:288.
    PubMed    


  4. ABUHASANEIN S, Edenbrandt L, Enqvist O, Jahnson S, et al
    A novel model of artificial intelligence based automated image analysis of CT urography to identify bladder cancer in patients investigated for macroscopic hematuria.
    Scand J Urol. 2024;59:90-97.
    PubMed    
    Abstract available

  5. XIA L, Dadabhoy A, Wood EL, Mehta SV, et al
    Pathologic and survival outcomes following radical cystectomy for "progressive" and "de novo" muscle-invasive bladder cancer: A meta-analysis stratified by neoadjuvant chemotherapy status.
    Urol Oncol. 2024 May 1:S1078-1439(24)00438-1. doi: 10.1016/j.urolonc.2024.
    PubMed    
    Abstract available


  6. Erdafitinib (Balversa) for urothelial carcinoma.
    Med Lett Drugs Ther. 2024;66:e83-e84.
    PubMed    


  7. KOSHKIN VS
    Therapy Attrition and Lessons for Future Approaches to Treatment of Advanced Urothelial Cancer.
    JAMA Netw Open. 2024;7:e249426.
    PubMed    


  8. MATHEW THOMAS V, Jo Y, Tripathi N, Roy S, et al
    Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US.
    JAMA Netw Open. 2024;7:e249417.
    PubMed    
    Abstract available

  9. ZHAO F, Jia Z, Xie H
    Identification of a pyroptosis-immune-related lncRNA signature for prognostic and immune landscape prediction in bladder cancer patients.
    Discov Oncol. 2024;15:140.
    PubMed    
    Abstract available

  10. MENECEUR S, De Vos CE, Petzsch P, Kohrer K, et al
    New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma.
    J Cell Mol Med. 2024;28:e18342.
    PubMed    
    Abstract available

  11. BEN-DAVID R, Galsky MD, Sfakianos JP
    Novel bladder-sparing approaches in patients with muscle-invasive bladder cancer.
    Trends Mol Med. 2024 Apr 30:S1471-4914(24)00092.
    PubMed    
    Abstract available

  12. LI J, Cheng C, Zhang J
    Autoimmune diseases and the risk of bladder cancer: A Mendelian randomization analysis.
    J Autoimmun. 2024;146:103231.
    PubMed    
    Abstract available

  13. LENIS AT, Whiting K, Ravichandran V, Tallman JE, et al
    Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer.
    JCO Precis Oncol. 2024;8:e2300274.
    PubMed    
    Abstract available

  14. LI T, You Q, Zhang S, Li R, et al
    Performance of (18)F-FDG PET/MRI and its parameters in staging and neoadjuvant therapy response evaluation in bladder cancer.
    iScience. 2024;27:109657.
    PubMed    
    Abstract available

  15. GADE VKV, Yadav BS
    Understanding the role of transmembrane 9 superfamily member 1 in bladder cancer pathogenesis.
    World J Clin Oncol. 2024;15:468-471.
    PubMed    
    Abstract available

  16. ZHANG W, Chen XS, Wei Y, Wang XM, et al
    Overexpressed KCNK1 regulates potassium channels affecting molecular mechanisms and biological pathways in bladder cancer.
    Eur J Med Res. 2024;29:257.
    PubMed    
    Abstract available

  17. SCIMECA M, Bischof J, Bonfiglio R, Nale E, et al
    Molecular profiling of a bladder cancer with very high tumour mutational burden.
    Cell Death Discov. 2024;10:202.
    PubMed    
    Abstract available

  18. INGRAM JW, Chung R, Laplaca C, McKiernan JM, et al
    Incidence and management of prostatic urethra recurrence in a cohort of 21 patients who received BCG induction for non-muscle invasive bladder cancer.
    Urol Oncol. 2024 Apr 29:S1078-1439(24)00436.
    PubMed    
    Abstract available

  19. SUARTZ CV, Martinez LM, Cordeiro MD, Botelho LAA, et al
    Honing the Hunt: A Comprehensive Review of Cell-free Tumor DNA to Predict Neoadjuvant Therapy Efficacy in Bladder Cancer.
    Clin Genitourin Cancer. 2024;22:102087.
    PubMed    
    Abstract available

  20. REDDY AC, Gu JZ, Koo BH, Fruh V, et al
    Urothelial Carcinoma: Epidemiology and Imaging-Based Review.
    R I Med J (2013). 2024;107:26-32.
    PubMed    
    Abstract available

  21. LIEDBERG F, Hagberg O, Aljabery F, Andren O, et al
    Cystectomy for bladder cancer in Sweden - short-term outcomes after centralization.
    Scand J Urol. 2024;59:84-89.
    PubMed    
    Abstract available

  22. LI J
    Correlation between Ki-67 or Profilin-1 Expression Levels, Clinicopathological Characteristics and Postoperative Prognosis in Patients with Bladder Cancer.
    Ann Ital Chir. 2024;95:246-252.
    PubMed    
    Abstract available

  23. YOUSSEF M, Sewell J, Grills R
    Unrecognised paraganglioma of the urinary bladder precipitating hypertensive crisis.
    BMJ Case Rep. 2024;17:e259283.
    PubMed    
    Abstract available

  24. LIN P, Yang X, Wang L, Zou X, et al
    Novel artesunate-metformin conjugate inhibits bladder cancer cell growth associated with Clusterin/SREBP1/FASN signaling pathway.
    Korean J Physiol Pharmacol. 2024;28:219-227.
    PubMed    
    Abstract available

  25. LIU S, Wang Y, Duan L, Cui D, et al
    Whole transcriptome sequencing identifies a competitive endogenous RNA network that regulates the immunity of bladder cancer.
    Heliyon. 2024;10:e29344.
    PubMed    
    Abstract available

  26. YIN C, Liufu C, Zhu T, Ye S, et al
    Bladder Cancer in Exosomal Perspective: Unraveling New Regulatory Mechanisms.
    Int J Nanomedicine. 2024;19:3677-3695.
    PubMed    
    Abstract available

  27. GARCIA-PERDOMO HA, Davila-Raigoza AM, Korkes F
    Metabolomics for the diagnosis of bladder cancer: A systematic review.
    Asian J Urol. 2024;11:221-241.
    PubMed    
    Abstract available

  28. WANG LS, Hubbard RA, Mamtani R
    Comparing survival in trial- versus routine-care advanced urothelial cancer patients on immune checkpoint blockade.
    Pharmacoepidemiol Drug Saf. 2024;33:e5798.
    PubMed    
    Abstract available

  29. PELLEGRINO F, Leni R, Basile G, Rosiello G, et al
    Peri- and post-operative outcomes of robot-assisted radical cystectomy after the implementation of the EAU guidelines recommendations for collecting and reporting complications at a high-volume referral center.
    World J Urol. 2024;42:270.
    PubMed    
    Abstract available

  30. CHEN L, Liu LT, Sun MJ, He SR, et al
    [Practical application of the Paris system for reporting urinary cytology].
    Zhonghua Bing Li Xue Za Zhi. 2024;53:470-476.
    PubMed    
    Abstract available

  31. ZHANG R, Jia S, Zhai L, Wu F, et al
    Predicting preoperative muscle invasion status for bladder cancer using computed tomography-based radiomics nomogram.
    BMC Med Imaging. 2024;24:98.
    PubMed    
    Abstract available

  32. BANG BR, Zhong J, Oh TJ, Lee JY, et al
    A Streamlined PENK Methylation Test in Urine DNA, EarlyTect BCD, Effectively Detects Bladder Cancer in Patients with Hematuria.
    J Mol Diagn. 2024 Apr 25:S1525-1578(24)00084.
    PubMed    
    Abstract available

  33. LU C, Gao H, Li H, Luo N, et al
    A novel LINC02321 promotes cell proliferation and decreases cisplatin sensitivity in bladder cancer by regulating RUVBL2.
    Transl Oncol. 2024;45:101962.
    PubMed    
    Abstract available

  34. ETURI A, Bhasin A, Zarrabi KK, Tester WJ, et al
    Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma.
    Molecules. 2024;29:1896.
    PubMed    
    Abstract available

  35. PEZZICOLI G, Ciciriello F, Musci V, Minei S, et al
    Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma.
    Medicina (Kaunas). 2024;60:585.
    PubMed    
    Abstract available

  36. MONYOK A, Mansour B, Vadnay I, Makra N, et al
    Change in Tissue Microbiome and Related Human Beta Defensin Levels Induced by Antibiotic Use in Bladder Carcinoma.
    Int J Mol Sci. 2024;25:4562.
    PubMed    
    Abstract available

  37. SANGUEDOLCE F, Falagario UG, Zanelli M, Palicelli A, et al
    Integrating the PD-L1 Prognostic Biomarker in Non-Muscle Invasive Bladder Cancer in Clinical Practice-A Comprehensive Review on State-of-the-Art Advances and Critical Issues.
    J Clin Med. 2024;13:2182.
    PubMed    
    Abstract available

  38. SARRIO-SANZ P, Martinez-Cayuelas L, Beltran-Perez A, Munoz-Montoya M, et al
    A Novel Decision Tree Model for Predicting the Cancer-Specific Survival of Patients with Bladder Cancer Treated with Radical Cystectomy.
    J Clin Med. 2024;13:2177.
    PubMed    
    Abstract available

  39. STROMME O, Heck KA, Brede G, Lindholm HT, et al
    tRNA-Derived Fragments as Biomarkers in Bladder Cancer.
    Cancers (Basel). 2024;16:1588.
    PubMed    
    Abstract available

  40. TOTONJI S, Ramos-Triguero A, Willmann D, Sum M, et al
    Lysine Methyltransferase 9 (KMT9) Is an Actionable Target in Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2024;16:1532.
    PubMed    
    Abstract available

  41. KAPRINIOTIS K, Tzelves L, Lazarou L, Mitsogianni M, et al
    Circulating Tumour DNA and Its Prognostic Role in Management of Muscle Invasive Bladder Cancer: A Narrative Review of the Literature.
    Biomedicines. 2024;12:921.
    PubMed    
    Abstract available

  42. SLUSARCZYK A, Ismail H, Zapala L, Piecha T, et al
    ASO Visual Abstract: Changes in the Urinary Microbiome following Transurethral Resection of Non-muscle-invasive Bladder Cancer-Insights from a Prospective Observational Study.
    Ann Surg Oncol. 2024 Apr 26. doi: 10.1245/s10434-024-15340.
    PubMed    


  43. MULLARD A
    First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer.
    Nat Rev Drug Discov. 2024 Apr 26. doi: 10.1038/d41573-024-00073.
    PubMed    


  44. LIN YH, Tsai HY, Tsao SH
    Re: Steven Monda, Manolis Pratsinis, Hansen Lui, et al. Secondary Bladder Cancer After Prostate Cancer Treatment: An Age-matched Comparison Between Radiation and Surgery. Eur Urol Focus. In press. http://doi.org/10.1016/j.euf.2023.09.002.
    Eur Urol Focus. 2024 Apr 25:S2405-4569(24)00061.
    PubMed    


  45. MELGAREJO SEGURA MT, Yanez Castillo Y, Lozano Lorca M, Morales Martinez A, et al
    Efficacy of conduction hyperthermia in the treatment of non-muscle invasive bladder cancer: A systematic review.
    Urol Oncol. 2024 Apr 25:S1078-1439(24)00399.
    PubMed    
    Abstract available

  46. REWARI H, Wadhwa P, Talwar H, Taneja D, et al
    Anastomosing haemangioma of adrenal gland: an unusual vascular tumour.
    BMJ Case Rep. 2024;17:e259092.
    PubMed    
    Abstract available

  47. FUJIWARA Y, Karol AB, Joshi H, Reford E, et al
    C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis.
    Crit Rev Oncol Hematol. 2024;197:104352.
    PubMed    
    Abstract available

  48. LIU MA, Li JW, Runcie K
    Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma.
    Curr Oncol Rep. 2024;26:496-503.
    PubMed    
    Abstract available

  49. RUSCHOFF J, Kumar G, Badve S, Jasani B, et al
    Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments.
    Virchows Arch. 2024;484:597-608.
    PubMed    
    Abstract available

  50. MAMTANI R, Tsingas K, Parikh RB, Elsouda D, et al
    Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer.
    Urol Oncol. 2024;42:177.
    PubMed    
    Abstract available

  51. PARK JY, Yu J, Kim CS, Kim YK, et al
    Reply for Comment on: Vitamin C and catheter-related bladder discomfort after transurethral resection of bladder tumor.
    J Clin Anesth. 2024;95:111445.
    PubMed    


  52. BHARTI AM, Rakesh Kumar RK, Chuang CH, Shaikh MO, et al
    Universal nanocomposite coating with antifouling and redox capabilities for electrochemical affinity biosensing in complex biological fluids.
    Nanoscale Horiz. 2024;9:843-852.
    PubMed    
    Abstract available

  53. FANG AM, Hayek O, Kaylor JM, Peyton CC, et al
    Postoperative Outcomes and Analgesic Requirements of Single-Port vs Multiport Robotic-Assisted Radical Cystectomy.
    J Endourol. 2024;38:438-443.
    PubMed    
    Abstract available

  54. BERTUCCI F, de Nonneville A, Finetti P, Cohendet A, et al
    The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer.
    Ann Oncol. 2024;35:477-478.
    PubMed    


  55. AI J, Zhang S, Qian Y, Kang L, et al
    Radiotherapy and Anrotinib in Malignant Glomus Tumor of the Bladder: A Case Report and Literature Review.
    Cancer Biother Radiopharm. 2024;39:318-321.
    PubMed    
    Abstract available

  56. SAUNDERS KE, Gerken N, Khani F, Williamson SR, et al
    Current gross examination and reporting patterns of post-neoadjuvant chemotherapy cystectomy specimens: Is it time for a standardized approach?
    Am J Clin Pathol. 2024;161:483-489.
    PubMed    
    Abstract available

  57. PARIS A, Bodaghi B, Touhami S
    Pan fibroblast growth factor receptor inhibitor associated retinopathy.
    Eur J Ophthalmol. 2023 Dec 12:11206721231220334. doi: 10.1177/11206721231220334.
    PubMed    
    Abstract available

  58. MARVASO G, Vitullo A, Corrao G, Vincini MG, et al
    Muscle-invasive bladder cancer in elderly and frail people: Is hypofractionated radiotherapy a feasible approach when no other local options are available?
    Tumori. 2024 May 10:3008916241252326. doi: 10.1177/03008916241252326.
    PubMed    
    Abstract available

  59. SHARMA AP, Singh PP, Chauhan R, Panda I, et al
    Clinical study of steroid receptors in nonmuscle invasive bladder cancer: A domain worth revisiting.
    Indian J Urol. 2024;40:127-132.
    PubMed    
    Abstract available

  60. ZHAN T, Li X, Liu J, Ye C, et al
    CRISPR-based gene expression platform for precise regulation of bladder cancer.
    Cell Mol Biol Lett. 2024;29:66.
    PubMed    
    Abstract available

  61. SHINDO T, Hashimoto K, Fujino K, Takahashi A, et al
    Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era.
    World J Urol. 2024;42:307.
    PubMed    
    Abstract available

  62. MACDONALD A, Bao L, Mehrnoush V, Ismail A, et al
    Does intravesical BCG for bladder cancer protect from COVID-19?
    Arch Ital Urol Androl. 2024 May 9:12449. doi: 10.4081/aiua.2024.12449.
    PubMed    
    Abstract available

  63. LI J, Li H, Yang Y, Sen Y, et al
    miRNA-143 as a potential biomarker in the detection of bladder cancer: a meta-analysis.
    Future Oncol. 2024 May 9. doi: 10.2217/fon-2023-0922.
    PubMed    
    Abstract available

  64. PLOUVIER SD, Marcq G, Vankemmel O, Colin P, et al
    Practice patterns and survival outcomes for Muscle-Invasive Bladder Cancer: real-life experience in a general population setting.
    Int J Qual Health Care. 2024 May 6:mzae040. doi: 10.1093.
    PubMed    
    Abstract available

  65. LICHTBROUN B, Ghodoussipour S, Packiam VT
    Ablative therapy with UGN-102 for low-grade intermediate risk non-muscle-invasive bladder cancer: ready for primetime?
    Transl Androl Urol. 2024;13:647-649.
    PubMed    


  66. GONZALEZ-PADILLA DA, Subiela JD, Villacampa-Auba F
    Chemoablation with UGN-102 in intermediate-risk non-muscle invasive bladder cancer, are we there yet?
    Transl Androl Urol. 2024;13:639-642.
    PubMed    


  67. VEDELD HM, Pharo H, Sorbo AK, Brandt-Winge S, et al
    Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer.
    Mol Oncol. 2024 May 8. doi: 10.1002/1878-0261.13639.
    PubMed    
    Abstract available

  68. YIN T, Mou S, Zhang H, Dong Y, et al
    CXCL10 could be a prognostic and immunological biomarker in bladder cancer.
    Discov Oncol. 2024;15:148.
    PubMed    
    Abstract available

  69. CHOI J, Lee J, Hwang YB, Jeong BC, et al
    Preoperative smoking and robot-assisted radical cystectomy outcomes & complications in multicenter KORARC database.
    Sci Rep. 2024;14:10550.
    PubMed    
    Abstract available

  70. CHENG K, Wan S, Chen SY, Yang JW, et al
    Nuclear matrix protein 22 in bladder cancer.
    Clin Chim Acta. 2024 May 6:119718. doi: 10.1016/j.cca.2024.119718.
    PubMed    
    Abstract available

  71. SUGUMAR K, De Mond J, Vijay A, Paramesh AS, et al
    Bile Spillage as a Prognostic Factor for Gall Bladder Cancer: A Systematic Review and Meta-analysis.
    J Surg Res. 2024;299:94-102.
    PubMed    
    Abstract available

  72. KHWAJA SA, Caglic I, Shaida N, Colquhoun AJ, et al
    Evaluation of magnetic resonance imaging for bladder cancer detection following transurethral resection of bladder tumour (TURBT).
    Abdom Radiol (NY). 2024 May 8. doi: 10.1007/s00261-024-04235.
    PubMed    
    Abstract available

  73. CHEN W, Wang Y, Hu H, Zhu Y, et al
    NIR-II light powered hydrogel nanomotor for intravesical instillation with enhanced bladder cancer therapy.
    Nanoscale. 2024 May 8. doi: 10.1039/d4nr01128.
    PubMed    
    Abstract available

  74. GHORBANI H, AfzalAghai M, Soltani S, Mottaghi M, et al
    Translation, Linguistic Validation, and Cultural Adaptation of the Bladder Cancer Index (BCI) Questionnaire Into the Persian (Farsi) Language and Comparing it With WHO Quality of Life Questionnaire: An Observational Study.
    J Family Reprod Health. 2023;17:128-135.
    PubMed    
    Abstract available

  75. FENG L, Huang G, Peng L, Liang R, et al
    Comparison of bladder carcinogenesis biomarkers in the urine of traditional cigarette users and e-cigarette users.
    Front Public Health. 2024;12:1385628.
    PubMed    
    Abstract available

  76. ZHOU Y, Zheng X, Sun Z, Wang B, et al
    Analysis of Bladder Cancer Staging Prediction Using Deep Residual Neural Network, Radiomics, and RNA-Seq from High-Definition CT Images.
    Genet Res (Camb). 2024;2024:4285171.
    PubMed    
    Abstract available

  77. HU H
    Effectiveness and Safety of Extended Lymph Node Dissection during Radical Surgery in Patients with Bladder Cancer: A Meta-Analysis.
    Arch Esp Urol. 2024;77:303-314.
    PubMed    
    Abstract available

  78. CHENG G, Zhou Z, Li S, Yang S, et al
    Predicting bladder cancer survival with high accuracy: insights from MAPK pathway-related genes.
    Sci Rep. 2024;14:10482.
    PubMed    
    Abstract available

  79. KIM DH, Choi MS, Choi JH, Lee C, et al
    Correlation between urine cytology results on the day after overnight continuous saline irrigation following transurethral resection of bladder tumor and bladder tumor recurrence.
    Investig Clin Urol. 2024;65:279-285.
    PubMed    
    Abstract available

  80. QIN R, Ma X, Pu S, Shen C, et al
    Identification and validation of a signature based on myofibroblastic cancer-associated fibroblast marker genes for predicting prognosis, immune infiltration, and therapeutic response in bladder cancer.
    Investig Clin Urol. 2024;65:263-278.
    PubMed    
    Abstract available

  81. KANG H, Suh J, You D, Jeong IG, et al
    Risk factors for failing to complete gemcitabine-cisplatin neoadjuvant chemotherapy in muscle invasive bladder cancer patients.
    Investig Clin Urol. 2024;65:256-262.
    PubMed    
    Abstract available

  82. CHOI J, Kim KH, Kim HS, Yoon HS, et al
    Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette-Guerin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective m
    Investig Clin Urol. 2024;65:248-255.
    PubMed    
    Abstract available

  83. PAK S, Park SG, Park J, Cho ST, et al
    Applications of artificial intelligence in urologic oncology.
    Investig Clin Urol. 2024;65:202-216.
    PubMed    
    Abstract available

  84. VALIZADEH S, Taghiyar S, Vahidi S, Abazari O, et al
    Application of PLK1 and HOXA13 Gene Expression Levels in Urine in the Diagnosis of Non-muscle Invasive Bladder Cancer.
    Biochem Genet. 2024 May 7. doi: 10.1007/s10528-024-10735.
    PubMed    
    Abstract available

  85. LIN YZ, Liu WH, Wu YP, Cai H, et al
    Revealing the potential of solute carrier family 31 (copper transporters), member 1: Insights into its role in bladder cancer progression and therapeutic implications.
    Int J Immunopathol Pharmacol. 2024;38:3946320241240706.
    PubMed    
    Abstract available

  86. ECKE TH, Wirtz RM, Heidenreich A, Fussel S, et al
    [Multicenter networks, innovative concepts, and basic research-the mixture is important: report from the 14th symposium of the German Research Group on Bladder Cancer (DFBK) in Cologne].
    Urologie. 2024 May 6. doi: 10.1007/s00120-024-02353.
    PubMed    


  87. YAO Z, Yang L, Yang X, Liu F, et al
    Stimulator of interferon genes mediated immune senescence reveals the immune microenvironment and prognostic characteristics of bladder cancer.
    Heliyon. 2024;10:e28803.
    PubMed    
    Abstract available

  88. YANG J, Liu X, Dai G, Qu L, et al
    Erratum: CircNT5E promotes the proliferation and migration of bladder cancer via sponging miR-502-5p: Erratum.
    J Cancer. 2024;15:3152-3153.
    PubMed    
    Abstract available

  89. ZHENG Y, Shi H, Hai B, Zhang J, et al
    A commentary on "A CT-based deep learning model predicts overall survival in patients with muscle invasive bladder cancer after radical cystectomy: a multicenter retrospective cohort study".
    Int J Surg. 2024 May 3. doi: 10.1097/JS9.0000000000001510.
    PubMed    


  90. LIU Y, Zhang X, Shang P
    Comment on 'HER2 overexpression predicts pathological T2 stage and improved survival in de novo muscle-invasive bladder cancer after immediate radical cystectomy: a retrospective cohort study'.
    Int J Surg. 2024 May 3. doi: 10.1097/JS9.0000000000001527.
    PubMed    


  91. BUKAVINA L, Helstrom E, Wallis CJD, Fulmes A, et al
    Association Between GLP1R Agonists and Prostate, Kidney, and Bladder Cancers.
    Eur Urol Oncol. 2024 May 2:S2588-9311(24)00098-1. doi: 10.1016/j.euo.2024.
    PubMed    


  92. MELCHIODE Z, Hu S, Xu J, Riveros C, et al
    Contemporary morbidity and mortality of open versus robotic cystectomy for bladder cancer: An analysis of the National Surgical Quality Improvement Program (NSQIP) procedure targeted cystectomy database.
    Urol Oncol. 2024 May 2:S1078-1439(24)00404-6. doi: 10.1016/j.urolonc.2024.
    PubMed    
    Abstract available

  93. ISAACS LL, Gonzalez NJ
    The Missing Trial Variable: A Case Report on Dietary Modification in a Patient with Durable Complete Remission After an Immunotherapy Clinical Trial for Metastatic Bladder Cancer.
    Altern Ther Health Med. 2024 May 3:AT9333.
    PubMed    
    Abstract available

  94. AESCHLIMANN L, Kehl A, Guscetti F, Posthaus C, et al
    Effective detection of BRAF(V595E) mutation in canine urothelial and prostate carcinomas using immunohistochemistry.
    Vet Comp Oncol. 2024;22:295-302.
    PubMed    
    Abstract available

  95. BAJEOT AS, Roumiguie M
    [Not Available].
    Ann Pathol. 2024;44:183-187.
    PubMed    


  96. CANAKCI C, Ozkaptan O, Dincer E, Ipek OM, et al
    Perioperative Outcomes of Open Extra-peritoneal Versus Laparoscopic Radical Cystoprostatectomy: A single Center Comparative Study.
    Urol J. 2024;21:175-181.
    PubMed    
    Abstract available

  97. CAI Z, Cheng X, Liao S, Zou W, et al
    POU2F3-positive small cell carcinoma of the bladder: A clinicopathologic analysis of 4 cases and literature review.
    Pathol Res Pract. 2024;257:155296.
    PubMed    
    Abstract available

  98. LACOSTE-COLLIN L
    [What contribution can make artificial intelligence to urinary cytology?].
    Ann Pathol. 2024;44:195-203.
    PubMed    
    Abstract available

  99. IRWIN T, Donlan AW, Owens L, Alvarez R, et al
    Enhancing upper tract urothelial carcinoma diagnosis: Utility of cytokeratin 17 and CK20/CD44/p53 immunohistochemical panel.
    Hum Pathol. 2024;146:43-48.
    PubMed    
    Abstract available

  100. GUERRERO-RAMOS F, Alvarez-Maestro M, Pinto Marin A, Dominguez Escrig JL, et al
    Multidisciplinary consensus document on the current treatment of bacille Calmette-Guerin-unresponsive non-muscle invasive bladder tumor.
    Actas Urol Esp (Engl Ed). 2024;48:262-272.
    PubMed    
    Abstract available

  101. SONG W, Yu J, Jeong BC
    ASO Author Reflections: Advancing Early Outcome Assessment in Robot-Assisted Radical Cystectomy: RARC Tetrafecta.
    Ann Surg Oncol. 2024;31:3908-3909.
    PubMed    


  102. BRAMAN SL, Peterson H, Elbe A, Mani E, et al
    Urinary and household chemical exposures in pet dogs with urothelial cell carcinoma.
    Vet Comp Oncol. 2024;22:217-229.
    PubMed    
    Abstract available

  103. JIN K, Xu J, Su X, Xu Z, et al
    TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.
    J Pathol. 2024;263:139-149.
    PubMed    
    Abstract available

  104. WANG XJ, Qiu X
    A case of primary small-cell neuroendocrine carcinoma of the bladder.
    Asian J Surg. 2024;47:2421-2422.
    PubMed    


  105. WANG Z, Bi H, Wang YD, Liu Q, et al
    Tislelizumab, a novel PD-1 monoclonal antibody in urothelial cancer: A real-world study.
    Actas Urol Esp (Engl Ed). 2024;48:295-303.
    PubMed    
    Abstract available

  106. LI Z, Xu Z, Wang J, Wang M, et al
    Nomograms for predicting the overall and cancer-specific survival in patients with non-urothelial carcinoma of the bladder: A population-based study.
    Biomol Biomed. 2024;24:633-646.
    PubMed    
    Abstract available

  107. LI J, Kong Z, Qi Y, Wang W, et al
    Single-cell and bulk RNA-sequence identified fibroblasts signature and CD8+ T-cell - fibroblast subtype predicting prognosis and immune therapeutic response of bladder cancer, based on machine-learning bioinformatics retrospective study.
    Int J Surg. 2024 May 17. doi: 10.1097/JS9.0000000000001516.
    PubMed    
    Abstract available

  108. QIU Y, Jiang Z, Zhang J
    Causal effects of BMI, waist circumference, and body fat percentage on the risk of bladder cancer: A Mendelian randomization study.
    Medicine (Baltimore). 2024;103:e38231.
    PubMed    
    Abstract available

  109. EKICI M, Demir E, Aydin C, Caglayan MS, et al
    Can the use of antithrombotic drugs be a predictive factor in the early diagnosis of bladder cancer?: A single-center analysis.
    Medicine (Baltimore). 2024;103:e38228.
    PubMed    
    Abstract available

  110. ZAWKY M, Elsayed A, Awadallah A, Abdelhalim A, et al
    The impact of purified protein derivative prior to intravesical bacillus Calmette-Guerin for the treatment of patients with non-muscle invasive bladder cancer.
    Minerva Urol Nephrol. 2024 May 17. doi: 10.23736/S2724-6051.23.05515.
    PubMed    
    Abstract available

  111. SERRETTA V
    BCG and bladder cancer. Forty-eight years after Morales report.
    Urologia. 2024 May 17:3915603241252909. doi: 10.1177/03915603241252909.
    PubMed    
    Abstract available

  112. QIAO X, Xue R, Li S, Li J, et al
    Expression of LASS2 Can be Regulated by Dihydroartemisinin to Regulate Cisplatin Chemosensitivity in Bladder Cancer Cells.
    Curr Pharm Biotechnol. 2024 May 16. doi: 10.2174/0113892010305651240514100129.
    PubMed    
    Abstract available

  113. LIAO G, Chen F, Zhong J, Jiang X, et al
    [Retracted] MicroRNA?539 inhibits the proliferation and invasion of bladder cancer cells by regulating IGF?1R.
    Mol Med Rep. 2024;30:116.
    PubMed    
    Abstract available

  114. LI R, Ning Y, Yuan Y, Yang X, et al
    Molecular mechanisms of ferroptosis and its effects on bladder cancer.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024;49:286-295.
    PubMed    
    Abstract available

  115. GUTMANN M, Ertl IE, Herek P, Vician P, et al
    Clofarabine Has a Superior Therapeutic Window as compared to Gemcitabine in Preclinical Bladder Cancer Models.
    Eur Urol Oncol. 2024 May 15:S2588-9311(24)00115.
    PubMed    
    Abstract available

  116. FLAIG TW, Spiess PE, Abern M, Agarwal N, et al
    Bladder Cancer, Version 3.2024.
    J Natl Compr Canc Netw. 2024;22:216-225.
    PubMed    
    Abstract available

  117. GUO L, Cid A, Cucci J, Kunkel B, et al
    Acu-URO17 is a highly sensitive and specific bladder cancer biomarker.
    BJUI Compass. 2024;5:497-501.
    PubMed    
    Abstract available

  118. PAN YC, Chu PY, Lin CC, Hsieh CY, et al
    Glutathione S-transferase omega class 1 (GSTO1)-associated large extracellular vesicles are involved in tumor-associated macrophage-mediated cisplatin resistance in bladder cancer.
    Mol Oncol. 2024 May 15. doi: 10.1002/1878-0261.13659.
    PubMed    
    Abstract available


  119. Retraction: Wang C, Chen Z, Ge Q, Hu J, Li F, Hu J, Xu H, Ye Z, Li LC (2014) Up-regulation of p21(WAF1/CIP1) by miRNAs and its implications in bladder cancer cells. FEBS Letters 588, 4654-4664. https://doi.org/10.1016/j.febslet.2014.10.037.
    FEBS Lett. 2024 May 15. doi: 10.1002/1873-3468.14892.
    PubMed    
    Abstract available

  120. QIAN L, Zhang Y, Chen H, Pang Y, et al
    The clinical effect of gratitude extension-construction theory nursing program on bladder cancer patients with fear of cancer recurrence.
    Front Oncol. 2024;14:1364702.
    PubMed    
    Abstract available

  121. FARKAS AM, Tran MA, Youssef D, Balan S, et al
    Natural Killer Cell Dysfunction In Human Bladder Cancer Is Caused By Tissue-Specific Suppression of SLAMF6 Signaling.
    bioRxiv [Preprint]. 2024 May 3:2024.04.30.591366. doi: 10.1101/2024.04.30.591366
    PubMed    
    Abstract available

  122. THEN CK, Paillas S, Moomin A, Misheva MD, et al
    Dietary fibre supplementation enhances radiotherapy tumour control and alleviates intestinal radiation toxicity.
    Microbiome. 2024;12:89.
    PubMed    
    Abstract available

  123. WANG Z, Zhang J, Luo L, Zhang C, et al
    Nucleoporin 93 Regulates Cancer Cell Growth and Stemness in Bladder Cancer via Wnt/beta-Catenin Signaling.
    Mol Biotechnol. 2024 May 14. doi: 10.1007/s12033-024-01184.
    PubMed    
    Abstract available

  124. ZHENG W, Zhang P, Yao C, Tao Y, et al
    The clinical significance of PD-1 expression in patients with bladder cancer without lymph node metastasis: a comparative study with drained lymph nodes and tumor tissues.
    Int J Neurosci. 2024 May 14:1-17. doi: 10.1080/00207454.2024.2356152.
    PubMed    
    Abstract available

  125. GINIL KUMAR P, Gideon M, Ravi Chandran K, Pullara SK, et al
    Our Experience of OSAKA Regimen (Bladder Preservation) in Patients with Advanced Bladder Cancer.
    Indian J Surg Oncol. 2024;15:264-267.
    PubMed    
    Abstract available

  126. NECCHI A, Roumiguie M, Kamat AM, Shore ND, et al
    Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial.
    Lancet Oncol. 2024 May 10:S1470-2045(24)00178.
    PubMed    
    Abstract available

  127. SCILIPOTI P, Liedberg F, Garmo H, Wilberg Orrason A, et al
    Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostat-ectomy. A nationwide population-based study.
    Scand J Urol. 2024;59:98-103.
    PubMed    
    Abstract available

  128. GRIFFIN RL, Shuman L, Yamashita H, Wu Q, et al
    The transcription factor sex-determining region Y-box 2 (SOX2) in bladder cancer.
    Am J Clin Exp Urol. 2024;12:88-99.
    PubMed    
    Abstract available

  129. LI DX, Yu QX, Wu RC, Wang J, et al
    Efficiency of bladder-sparing strategies for bladder cancer: an umbrella review.
    Ther Adv Med Oncol. 2024;16:17588359241249068.
    PubMed    
    Abstract available

  130. TUO Z, Lin Y, Zhang Y, Gao L, et al
    Prognostic significance and immune landscape of a cell cycle progression-related risk model in bladder cancer.
    Discov Oncol. 2024;15:160.
    PubMed    
    Abstract available

  131. TEMIRCAN Z
    Investigation of Knowledge, Attitudes, and Healthy Lifestyle Behaviors on Bladder Cancer in Turkey.
    J Med Invest. 2024;71.
    PubMed    
    Abstract available

  132. CANO VELASCO J, Artero Fullana S, Polanco Pujol L, Lafuente Puentedura A, et al
    Use of Bladder Epicheck(R) in the follow-up of high-risk non-muscle-invasive Bladder cancer: A systematic literature review.
    Actas Urol Esp (Engl Ed). 2024 May 10:S2173-5786(24)00064.
    PubMed    
    Abstract available

  133. BEN-DAVID R, Tillu N, Alerasool P, Bieber C, et al
    Induction and maintenance of sequential intravesical gemcitabine/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols.
    World J Urol. 2024;42:315.
    PubMed    
    Abstract available

  134. NAKAYAMA S, Yoda E, Yamashita S, Takamatsu Y, et al
    Knockdown of iPLA(2)gamma enhances cisplatin-induced apoptosis by increasing ROS-dependent peroxidation of mitochondrial phospholipids in bladder cancer cells.
    Free Radic Biol Med. 2024;220:301-311.
    PubMed    
    Abstract available

  135. OTERO-MURIEL IJ, Jimenez Giraldo S, Garcia-Perdomo HA
    The association between the human papillomavirus (HPV) and the diagnosis of bladder cancer: systematic review and meta-analysis.
    Actas Urol Esp (Engl Ed). 2024 May 9:S2173-5786(24)00062.
    PubMed    
    Abstract available

  136. TANG Z, Can L, Xuan S, Chen L, et al
    Unveiling the Etiology of Urological Tumors: A Systematic Review of Mendelian Randomization Applications in Renal Cell Carcinoma, Bladder Cancer, and Prostate Cancer.
    Urol J. 2024 May 11. doi: 10.22037/uj.v21i.7970.
    PubMed    
    Abstract available

  137. TYAGI P, Hafron J, Kaufman J, Chancellor M, et al
    Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration.
    Int J Mol Sci. 2024;25:4945.
    PubMed    
    Abstract available

  138. STURM S, Niegisch G, Windolf J, Suschek CV, et al
    Exposure of Bladder Cancer Cells to Blue Light (lambda = 453 nm) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic Efficiency of Gemcitabine.
    Int J Mol Sci. 2024;25:4868.
    PubMed    
    Abstract available

  139. DRACHNERIS J, Morkunas M, Fabijonavicius M, Cekauskas A, et al
    Spatial Distribution of Macrophage and Lymphocyte Subtypes within Tumor Microenvironment to Predict Recurrence of Non-Muscle-Invasive Papillary Urothelial Carcinoma after BCG Immunotherapy.
    Int J Mol Sci. 2024;25:4776.
    PubMed    
    Abstract available

  140. CONTIERI R, Pichler R, Del Giudice F, Marcq G, et al
    Variation in Follow-Up after Radical Cystectomy for Bladder Cancer-An Inventory Roundtable and Literature Review.
    J Clin Med. 2024;13:2637.
    PubMed    
    Abstract available

  141. SLUSARCZYK A, Garbas K, Pustula P, Zapala L, et al
    Assessing the Predictive Accuracy of EORTC, CUETO and EAU Risk Stratification Models for High-Grade Recurrence and Progression after Bacillus Calmette-Guerin Therapy in Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2024;16:1684.
    PubMed    
    Abstract available

  142. CHI J, Jiang X, Liu Q, Cui Y, et al
    Elevated expression of SRRM3 in bladder cancer predicts poor prognosis and is associated with immune infiltration.
    Asian J Surg. 2024 May 9:S1015-9584(24)00869.
    PubMed    


  143. WANG Y, Song Y, Peng Y, Han S, et al
    Effects of androgen suppression therapy on the incidence and prognosis of bladder cancer: An updated systematic review and meta-analysis.
    Urol Oncol. 2024 May 9:S1078-1439(24)00431-9. doi: 10.1016/j.urolonc.2024.
    PubMed    
    Abstract available

  144. LIU L, Xu L, Wu D, Zhu Y, et al
    Impact of tumour stroma-immune interactions on survival prognosis and response to neoadjuvant chemotherapy in bladder cancer.
    EBioMedicine. 2024;104:105152.
    PubMed    
    Abstract available

  145. XIN L, Xiao X, Xiao W, Peng R, et al
    Screening for urothelial carcinoma cells in urine based on digital holographic flow cytometry through machine learning and deep learning methods.
    Lab Chip. 2024;24:2736-2746.
    PubMed    
    Abstract available

  146. OLAH C, Kubik A, Matrai P, Engh MA, et al
    Estimation of the incidence of urachal cancer: A systematic review and meta-analysis of registry-based studies.
    Urol Oncol. 2024;42:221.
    PubMed    
    Abstract available

  147. PALERMO M, D'Elia C, Trenti E, Comploj E, et al
    Prospective evaluation of the RT-PCR based urinary marker Bladder Epicheck(R) as a diagnostic tool in upper urinary tract tumor.
    Minerva Urol Nephrol. 2024;76:195-202.
    PubMed    
    Abstract available

  148. BENJAMIN DJ, Rezazadeh Kalebasty A, Prasad V
    The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
    Eur Urol Oncol. 2024;7:313-315.
    PubMed    
    Abstract available

  149. WOO HK, Park J, Kim KH, Ku JY, et al
    Alix-normalized exosomal programmed death-ligand 1 analysis in urine enables precision monitoring of urothelial cancer.
    Cancer Sci. 2024;115:1602-1610.
    PubMed    
    Abstract available

  150. LI X, Huang J, Ji P
    Comment on 'Robot-assisted radical cystectomy with intracorporeal urinary diversion: an updated systematic review and meta-analysis of its differential effect on effectiveness and safety'.
    Int J Surg. 2024;110:3114-3115.
    PubMed    


  151. MAHLOW J, Gupta S
    Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical/treatment relevance.
    Urol Oncol. 2024;42:193-202.
    PubMed    
    Abstract available

  152. SAAL J, Grunwald V, Bald T, Ritter M, et al
    On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy.
    Eur Urol Oncol. 2024;7:328-331.
    PubMed    
    Abstract available

  153. MONTORSI F, Rosiello G, Gandaglia G, Salonia A, et al
    Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/1
    Eur Urol Oncol. 2024;7:636.
    PubMed    


  154. CHEN CH, Chen YC, Chang YC, Hung CH, et al
    Taurine Rescues Cancer-induced Atrophy in Human Skeletal Muscle Cells via Ameliorating the Inflammatory Tumor Microenvironment.
    Anticancer Res. 2024;44:1963-1971.
    PubMed    
    Abstract available

  155. KOBATAKE K, Ikeda K, Kohada Y, Tasaka R, et al
    Muscle-Invasive Bladder Cancer With Hydronephrosis Exhibits a High Frequency of Mutations in Fibroblast Growth Factor Receptor 3 Gene.
    Anticancer Res. 2024;44:1947-1954.
    PubMed    
    Abstract available

  156. HUBER F, Wolf I, Storz J, Schultze-Seemann S, et al
    Antibody-dye Conjugates Targeting EGFR and HER2 for the Photoimmunotherapy of Bladder Cancer.
    Anticancer Res. 2024;44:1837-1844.
    PubMed    
    Abstract available

  157. FUKUOKAYA W, Akazawa K, Kimura T
    Association Between Serum Magnesium Levels and Outcomes of Atezolizumab in Patients With Metastatic Urothelial Carcinoma.
    Anticancer Res. 2024;44:2117-2123.
    PubMed    
    Abstract available

  158. FUCHIZAWA H, Ando K, Motoi N, Iizuka T, et al
    STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-gamma-induced Apoptosis in Urothelial Cancer.
    Anticancer Res. 2024;44:1925-1930.
    PubMed    
    Abstract available

  159. BREE KK, Janes JL, Hensley PJ, Srinivasan A, et al
    Racial disparities in stage at bladder cancer diagnosis in the US Veterans Affairs healthcare system.
    BJU Int. 2024 Apr 29. doi: 10.1111/bju.16380.
    PubMed    
    Abstract available

  160. HAAS M, Kriegmair MC, Breyer J, Sikic D, et al
    Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert(R) BC Monitor.
    BJU Int. 2024 May 8. doi: 10.1111/bju.16389.
    PubMed    
    Abstract available

  161. PELLEGRINO F, Martini A, Falagario UG, Rautiola J, et al
    How can we reduce morbidity after robot-assisted radical cystectomy with intracorporeal neobladder? A report on postoperative complications by the European Association of Urology Robotic Urology Section Scientific Working Group.
    BJU Int. 2024;133:673-677.
    PubMed    


  162. JONES RT, Scholtes M, Goodspeed A, Akbarzadeh M, et al
    NPEPPS Is a Druggable Driver of Platinum Resistance.
    Cancer Res. 2024;84:1699-1718.
    PubMed    
    Abstract available

  163. MAGUIRE WF, Lee D, Weinstock C, Gao X, et al
    FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma.
    Clin Cancer Res. 2024;30:2011-2016.
    PubMed    
    Abstract available

  164. BALASOORIYA ER, Wu Q, Ellis H, Zhen Y, et al
    The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.
    Clin Cancer Res. 2024;30:2181-2192.
    PubMed    
    Abstract available

  165. OBIREDDY SR, Lai WF
    Advances in preclinical approaches for intravesical therapy of bladder cancer.
    Curr Opin Urol. 2024 May 17. doi: 10.1097/MOU.0000000000001186.
    PubMed    
    Abstract available

  166. ABSOLOM K, Rogers Z, Catto JWF, Bottomley S, et al
    Decision Regret Regarding Treatment Choices 1 Year After a New Diagnosis of Bladder Cancer.
    Eur Urol. 2024 May 11:S0302-2838(24)02346-7. doi: 10.1016/j.eururo.2024.
    PubMed    


  167. TILGENER C, Bedke J
    Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
    Eur Urol. 2024;85:591-592.
    PubMed    


  168. ROSENBERG JE, Mamtani R, Sonpavde GP, Loriot Y, et al
    Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.
    Eur Urol. 2024;85:574-585.
    PubMed    
    Abstract available

  169. KAWAI T, Matsuyama H, Kobayashi K, Ikeda A, et al
    Photodynamic diagnosis-assisted transurethral resection of bladder tumor for high-risk non-muscle invasive bladder cancer improves intravesical recurrence-free survival (BRIGHT study).
    Int J Urol. 2024 May 2. doi: 10.1111/iju.15483.
    PubMed    
    Abstract available

  170. MIYAKE M, Nishimura N, Nakahama T, Nishimoto K, et al
    Differences in oncological benefits from second transurethral resection between white-light initial surgery and photodynamic diagnosis-guided initial surgery for primary high-risk non-muscle invasive bladder cancer.
    Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15474.
    PubMed    
    Abstract available

  171. SHIOTA M, Nagakawa S, Tsukahara S, Matsumoto T, et al
    Independent validation of genetic risk model to progression after intravesical bacillus Calmette-Guerin therapy for non-muscle invasive bladder cancer.
    Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15484.
    PubMed    


  172. MIYAKE M
    Editorial Comment from Dr Miyake to Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node
    Int J Urol. 2024 May 3. doi: 10.1111/iju.15487.
    PubMed    


  173. KONDO T
    Editorial Comment to Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Int J Urol. 2024;31:560-561.
    PubMed    


  174. ISHIHARA H, Takagi T
    Editorial Comment on Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Int J Urol. 2024;31:559-560.
    PubMed    


  175. KITA Y, Otsuka H, Ito K, Hara T, et al
    Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Int J Urol. 2024;31:552-559.
    PubMed    
    Abstract available

  176. TANAKA T, Yamasaki K, Nofuji S, Maehana T, et al
    Development and preliminary evaluation of a novel procedure for creation of an ileal conduit stoma aimed at preventing parastomal hernia.
    Int J Urol. 2024;31:512-518.
    PubMed    
    Abstract available

  177. HAYAKAWA N, Kikuchi E
    Editorial Comment on "Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node classification
    Int J Urol. 2024 May 16. doi: 10.1111/iju.15495.
    PubMed    


  178. DAVID J, Pathak RA
    Editorial comment for "Surgeon-administered regional nerve blocks during radical cystectomy: a feasibility study".
    Int Urol Nephrol. 2024;56:1937-1938.
    PubMed    


  179. KARABURUN MC, Kuz ED, Akpinar C, Obaid K, et al
    Grade Heterogeneity in High-Grade Urothelial Carcinomas: Does It Have an Impact on the Survival of Patients With Intermediate/High-Risk Nonmuscle-Invasive Bladder Cancer Who Received Adequate Adjuvant Bacillus Calmette-Guerin Therapy?
    J Urol. 2024 May 1:101097JU0000000000003990. doi: 10.1097/JU.0000000000003990.
    PubMed    
    Abstract available

  180. NARAYAN VM, Boorjian SA, Alemozaffar M, Konety BR, et al
    Efficacy of Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non-muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial.
    J Urol. 2024 May 5:101097JU0000000000004020. doi: 10.1097/JU.0000000000004020.
    PubMed    
    Abstract available

  181. DJALADAT H, Ghoreifi A, Tejura T, Miranda G, et al
    Prophylactic Use of Biologic Mesh in Ileal Conduit (PUBMIC): A Randomized Clinical Trial.
    J Urol. 2024;211:743-753.
    PubMed    
    Abstract available

  182. CHO HJ, Chung HS, Hwang EC, Jung SI, et al
    Music from noise-canceling headphones is beneficial against anxiety in male bladder cancer patients undergoing follow-up cystoscopy: A prospective randomized trial.
    Urol Int. 2024 May 10. doi: 10.1159/000539312.
    PubMed    
    Abstract available

  183. EULE CJ, Warren A, Kuna EM, Callihan EB, et al
    Neoadjuvant cisplatin-based chemotherapy in nonmetastatic muscle-invasive bladder cancer: A systematic review and pooled meta-analysis to determine the preferred regimen.
    Urology. 2024 Apr 27:S0090-4295(24)00306-6. doi: 10.1016/j.urology.2024.
    PubMed    
    Abstract available

  184. PORTE F, Granghaud A, Chang J, Kearney M, et al
    Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France.
    PLoS One. 2024;19:e0302548.
    PubMed    
    Abstract available

  185. JING W, Wang G, Cui Z, Li X, et al
    Tumor-neutrophil cross talk orchestrates the tumor microenvironment to determine the bladder cancer progression.
    Proc Natl Acad Sci U S A. 2024;121:e2312855121.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.


;